1-3 of 3
Kathleen Turnbull, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment Of Early Cytogenetic Response By 3 Months Versus >3-6 Months Or No Response By 6 Months As a Predictor Of Long-Term Clinical Outcomes In a Phase 1/2 Study Of Bosutinib In Chronic Phase CML

Jorge E. Cortes, MD, H. Jean Khoury, MD, Andreas Hochhaus, MD, Jane F Apperley, MD, Stephen G. O'Brien, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Maureen G. Conlan, MD, Hagop M. Kantarjian, MD, Tim H. Brümmendorf, MD
Journal: Blood
Blood (2013) 122 (21): 1484.
https://doi.org/10.1182/blood.V122.21.1484.1484
Published: 2013
Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Carlo Gambacorti-Passerini, MD, Jeff H. Lipton, PhD, MD
Journal: Blood
Blood (2013) 122 (21): 2723.
https://doi.org/10.1182/blood.V122.21.2723.2723
Published: 2013
Journal Articles

Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update

Jorge E. Cortes, MD, H. Jean Khoury, MD, Hagop M. Kantarjian, MD, Jeff H. Lipton, MD, Dong-Wook Kim, MD, Maureen G. Conlan, MD, Eric Leip, PhD, Kathleen Turnbull, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2013) 122 (21): 4025.
https://doi.org/10.1182/blood.V122.21.4025.4025
Published: 2013